Document is current
Any future updates will be listed below
-
Authors
Hanson, Kent A. https://orcid.org/0000-0002-7201-3324
Ezzedine, Khaled https://orcid.org/0000-0002-5468-4589
Austin, Jenny https://orcid.org/0000-0003-4297-6290
Anderson, Peter https://orcid.org/0000-0002-2171-8228
Marwaha, Simran https://orcid.org/0000-0003-0380-0372
Kurosky, Samantha K. https://orcid.org/0000-0003-2392-8111
Adiri, Roni https://orcid.org/0009-0008-8944-8421
Piercy, James https://orcid.org/0000-0001-7015-1021
Law, Ernest H. https://orcid.org/0000-0002-6111-8008
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 21 March 2025
First Online: 10 April 2025
Declarations
:
: K.A. Hanson was a paid consultant for Pfizer during the period in which the work for this manuscript was conducted. K. Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. J. Austin, P. Anderson, S. Marwaha, and J. Piercy are employees of Adelphi Real World. S.K. Kurosky, R. Adiri, and E.H. Law are employees of and hold stock or stock options in Pfizer.
: Data were collected according to European Pharmaceutical Marketing Research Association guidelines, and the DSP protocol (21-ADRW-122) was submitted to the Pearl Institutional Review Board and was granted an exemption. Data were collected in full accordance with relevant legislation at the time. Informed consent was obtained from all individual participants included in the study. The manuscript does not include personal details or images that may lead to the identification of participants.
